97 related articles for article (PubMed ID: 2938660)
1. A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.
Newman HF; Bleehen NM; Workman P
Br J Radiol; 1986 Apr; 59(700):423-5. PubMed ID: 2938660
[No Abstract] [Full Text] [Related]
2. A phase I study of the combination of two hypoxic cell radiosensitizers, Ro 03-8799 and SR-2508: toxicity and pharmacokinetics.
Newman HF; Bleehen NM; Workman P
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1113-6. PubMed ID: 2943709
[TBL] [Abstract][Full Text] [Related]
3. Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts.
Taghian A; Lespinasse F; Guichard ME
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1535-40. PubMed ID: 1834621
[TBL] [Abstract][Full Text] [Related]
4. Gradient high-performance liquid chromatographic method for simultaneous assay of the radiosensitizers etanidazole (SR 2508) and pimonidazole (Ro 03-8799) in biological materials.
Ward R; Workman P
J Chromatogr; 1987 Sep; 420(1):223-7. PubMed ID: 2959677
[No Abstract] [Full Text] [Related]
5. The clinical testing of Ro 03-8799--pharmacokinetics, toxicology, tissue and tumor concentrations.
Saunders MI; Anderson PJ; Bennett MH; Dische S; Minchinton A; Stratford MR; Tothill M
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1759-63. PubMed ID: 6480459
[TBL] [Abstract][Full Text] [Related]
6. Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.
Coleman CN; Urtasun RC; Wasserman TH; Hancock S; Harris JW; Halsey J; Hirst VK
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1749-53. PubMed ID: 6237086
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of the hypoxic cell radiosensitizer Ro-03-8799.
Roberts JT; Bleehen NM; Workman P; Walton MI
Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1755-8. PubMed ID: 6480458
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
Eifel PJ; Brown JM
Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1311-4. PubMed ID: 6236186
[TBL] [Abstract][Full Text] [Related]
9. The radiosensitizer Ro 03-8799 and the concentrations which may be achieved in human tumours: a preliminary study.
Saunders MI; Dische S; Fermont D; Bishop A; Lenox-Smith I; Allen JG; Malcolm SL
Br J Cancer; 1982 Nov; 46(5):706-10. PubMed ID: 7171452
[TBL] [Abstract][Full Text] [Related]
10. Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).
Maughan TS; Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1990 May; 18(5):1151-6. PubMed ID: 2140825
[TBL] [Abstract][Full Text] [Related]
11. The multi-dose clinical tolerance and pharmacokinetics of the combined radiosensitizers, Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Ward R; Workman P; Bleehen NM
Int J Radiat Oncol Biol Phys; 1988 Nov; 15(5):1073-83. PubMed ID: 2972667
[TBL] [Abstract][Full Text] [Related]
12. A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Bleehen NM; Newman HF; Maughan TS; Workman P
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):1093-6. PubMed ID: 2539346
[TBL] [Abstract][Full Text] [Related]
13. Hypoxic cell radiosensitizers in the treatment of high grade gliomas: a new direction using combined Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).
Newman HF; Bleehen NM; Ward R; Workman P
Int J Radiat Oncol Biol Phys; 1988 Sep; 15(3):677-84. PubMed ID: 2843488
[TBL] [Abstract][Full Text] [Related]
14. Concentrations achieved in human tumors after administration of misonidazole, SR-2508 and Ro 03-8799.
Dische S; Saunders MI; Dunphy EP; Bennett MH; Des Rochers C; Stratford MR; Minchinton AI; Orchard RA
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1109-11. PubMed ID: 2943708
[TBL] [Abstract][Full Text] [Related]
15. Estimation of the hypoxic cell-sensitiser misonidazole and its O-demethylated metabolite in biological materials by reversed-phase high-performance liquid chromatography.
Workman P; Little CJ; Marten TR; Dale AD; Ruane RJ; Flockhart IR; Bleehen NM
J Chromatogr; 1978 May; 145(3):507-12. PubMed ID: 659541
[No Abstract] [Full Text] [Related]
16. Clinical trials with etanidazole (SR-2508) by the Radiation Therapy Oncology Group (RTOG).
Wasserman TH; Lee DJ; Cosmatos D; Coleman N; Phillips T; Davis L; Marcial V; Stetz J
Radiother Oncol; 1991; 20 Suppl 1():129-35. PubMed ID: 1826961
[TBL] [Abstract][Full Text] [Related]
17. Ocular penetration, toxicity, and radiosensitization effects of two hypoxic cell radiosensitizers on retinoblastoma.
Rootman J; Gallie B; Kumi C; Bussanich N; Rogers B; Palcic B
Arch Ophthalmol; 1986 Nov; 104(11):1693-7. PubMed ID: 2946282
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
White RA; Workman P; Brown JM
Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
[No Abstract] [Full Text] [Related]
19. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
Workman P
Cancer Clin Trials; 1980; 3(3):237-51. PubMed ID: 7438321
[TBL] [Abstract][Full Text] [Related]
20. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
Coleman CN; Halsey J; Cox RS; Hirst VK; Blaschke T; Howes AE; Wasserman TH; Urtasun RC; Pajak T; Hancock S
Cancer Res; 1987 Jan; 47(1):319-22. PubMed ID: 3024818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]